A phase I, randomized, placebo controlled, parallel group, single dose study to evaluate the effects of PF-00572778 [PF-572778] and alprazolam on a naloxone challenge in healthy adult subjects
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2009
At a glance
- Drugs Alprazolam; PF 572778
- Indications Generalised anxiety disorder
- Focus Pharmacodynamics
- Sponsors Pfizer
- 16 Sep 2009 Actual end date (Feb 2008) and actual number of patients (47) added as reported by ClinicalTrials.gov.
- 16 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 15 Jan 2008 New trial record.